| | Vol. 9.43 – 9 November, 2021 |
|
|
|
| Researchers showed that discoidin domain receptor 1 (DDR1), a collagen receptor with tyrosine kinase activity, instigated immune exclusion by promoting collagen fibre alignment. [Nature] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors identified the metabolite and neurotransmitter GABA as a candidate signaling molecule synthesized and secreted by activated B cells and plasma cells. [Nature] |
|
|
|
| Investigators showed that tumor-specific CD8+ tumor-infiltrating lymphocytes accumulated in tumor islets, where they engage antigen and upregulate PD-1, which restrained their functions. [Cancer Cell] |
|
|
|
| Researchers systematically applied Mendelian randomization, genetic colocalization, immune-cell-type enrichment, and phenome-wide association methods to investigate the effects of genetically predicted gene expression on ten immune-associated diseases and four cancer outcomes. [American Journal of Human Genetics] |
|
|
|
| Scientists describe a unique, sophisticated combinatorial platform for glioblastoma (GMB): a cooperative multifunctional immunotherapy based on genetically engineered human NK cells bearing multiple antitumor functions including local tumor responsiveness that addresses key drivers of GBM resistance to therapy [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Investigators used an in vitro peristaltic pump setup that mimiced pulsatile blood flow to determine if immune cells took up particles under constant fluidic flow. [Molecular Pharmaceutics] |
|
|
|
| The authors addressed the issue of endotoxin levels in laboratory grade Cas9 proteins used to measure T cell memory responses. [Gene Therapy] |
|
|
|
| Scientists reported a comprehensive pattern of homeodomain only protein (Hopx) expression in multiple types of immune cells under steady state conditions. [Heliyon] |
|
|
|
| By screening a collection of small-molecule compounds, investigators found that inhibiting β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) with MK-8931 potently reprogrammed tumor-promoting macrophages into tumor-suppressive macrophages and promotes macrophage phagocytosis of glioma cells. [Nature Cancer] |
|
|
|
|
| The authors summarize current knowledge on the unique contributions of the two hypoxia-inducible factor (HIF)-α isoforms to tumor progression in the context of the complex tumor immune microenvironment, highlighting important considerations for therapy. [Trends in Cancer] |
|
|
|
| Different immune cell subsets in perinatal brain injury including their infiltration routes are reviewed and critical aspects such as sex differences and maturational stage are discussed. [Pediatric Research] |
|
|
|
|
| Inspirna, Inc. announced a collaboration with Bristol Myers Squibb on a clinical trial of a combination therapy using RGX-104, the company’s small molecule agonist of the Liver X Receptor/Apolipoprotein E pathway, and Yervoy®, Bristol Myer Squibb’s Cytotoxic T-Lymphocyte Associated protein 4 inhibitor. [Inspirna, Inc.] |
|
|
|
| Australian clinical-stage drug development company Noxopharm has announced its DARRT-2 Phase II clinical trial has commenced with patient enrollment in the US. [Noxopharm] |
|
|
|
|
| November 22 – 23, 2021 Ghent, Belgium |
|
|
|
|
|
| Oregon Health & Science University – Portland, Oregon, United States |
|
|
|
| St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| Benaroya Research Institute at Virginia Mason – Seattle, Washington, United States |
|
|
|
| Calgary, Alberta, Canada – University of Calgary |
|
|
|
| The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
|